The PennZone

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 27, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) common stock between February 26, 2020 and April 19, 2022, inclusive (the "Class Period").

Investors suffering losses on their Natera investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, including Natera's Panorama test, alleging that positive results on tests are incorrect approximately 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which "can cost thousands of dollars, come with a small risk of miscarriage and can't be performed until later in pregnancy."

On this news, Natera's stock price fell $5.35, or 5.7%, over two trading days to close at $88.04 per share on January 4, 2022, thereby injuring investors.

Then, on January 14, 2022, a nonprofit watchdog group filed a complaint with the SEC requesting an investigation into whether Natera had "repeatedly" claimed that its tests were "much more reliable than it appears they really are."

More on The PennZone

• Elevate Your Sneakers With Crep Protect Trek Laces
• Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
• Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
• DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
• From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)

On this news, Natera's stock fell $6.29, or 9.3%, to close at $61.08 per share on January 18, 2022.

On March 9, 2022, Hindenburg Research published a report which alleged, among other things, that Natera's revenue growth has been "fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."

On this news, Natera's stock price fell $17.95, or 32.8%, to close at $36.80 per share on March 9, 2022, thereby further injuring investors.

Then, on March 14, 2022, a Delaware District Court jury found that Natera had engaged in false advertising, including claims that its kidney transplant test, Prospera, was more accurate than its competing tests.

On this news, Natera's stock price fell $5.57 per share, or 15.5%, to close at $30.32 per share on March 15, 2022, thereby further injuring investors.

Then, on April 19, 2022, the United States Food and Drug Administration ("FDA") issued a safety communication "to educate patients an health care providers and to help reduce the inappropriate use" of non-invasive prenatal tests ("NIPT"), cautioning that NIPTs reliability and accuracy "may not be supported with sound scientific evidence," revealing that there had been "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy."

On this news, Natera's stock fell $1.53, or 3.9%, to close at $38.63 per share on April 19, 2022, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

More on The PennZone

• SKRAP Finds Hope Through Heartache on Powerful New Single "Shellshock"
• CodesClue: A Trusted AI-Based Software Development Company for Global Businesses
• U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
• Valgar LLC Launches The Briefing Room: Education Leaders
• New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity

If you purchased or otherwise acquired Natera common stock during the Class Period, you may move the Court no later than June 27, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

---

Show All News | Disclaimer | Report Violation